...
首页> 外文期刊>Clinical and laboratory haematology >Expression of the vascular endothelial growth factor receptors 1 and 2 in acute myeloid leukemia: incidence and feasibility of immunohistochemical staining.
【24h】

Expression of the vascular endothelial growth factor receptors 1 and 2 in acute myeloid leukemia: incidence and feasibility of immunohistochemical staining.

机译:血管内皮生长因子受体1和2在急性髓细胞性白血病中的表达:免疫组化染色的发生率和可行性。

获取原文
获取原文并翻译 | 示例
           

摘要

Vascular endothelial growth factor (VEGF) and its receptor tyrosine kinases, VEGFR-1 and VEGFR-2, are important therapeutic targets for various cancers including AML. Paraffin-embedded bone marrow samples (PE-BM) are, in most cases, the only tissue accessible to perform retrospective analyses of novel targets such as VEGF and/or its receptors. As a result, it limits our options to immunohistochemistry (IHS), or more expensive and less practical techniques such as enzyme-linked immunosorbent assay (ELISA) or fluorescence in situ hybridization (FISH). We analyzed the feasibility of IHS to measure VEGFR-1 and VEGFR-2 expression in 28 AML samples using monoclonal antibodies (moAbs) against Flt-1 (VEGFR-1) and KDR/Flk-1 (VEGFR-2). Medical records were reviewed for relevant clinical information. Expression of VEGFR-1 (+) and VEGFR-2 (+) were seen in 25% (7/28) and 43% (12/28) respectively. Forty-six percent (13/28) were dual-negatives for VEGFR-1 and VEGFR-2; 14% (4/28) were dual-positives for VEGFR-1 and VEGFR-2. An inferior survival was observed in patients whose myeloblasts express either VEGFR-1 (+) or VEGFR-2 (+), or both. Determination of expression of VEGF receptors (1 and 2) by IHS in PE-BM tissue is feasible. Prospective comparison of IHC to flow cytometry or other molecular techniques, and assessment of the prognostic significance of VEGF receptors in AML patients is warranted.
机译:血管内皮生长因子(VEGF)及其受体酪氨酸激酶VEGFR-1和VEGFR-2是包括AML在内的多种癌症的重要治疗靶标。在大多数情况下,石蜡包埋的骨髓样本(PE-BM)是唯一可以对新靶标(例如VEGF和/或其受体)进行回顾性分析的组织。结果,它限制了我们对免疫组织化学(IHS)的选择,或更昂贵,更不实用的技术,例如酶联免疫吸附测定(ELISA)或荧光原位杂交(FISH)。我们分析了IHS使用抗Flt-1(VEGFR-1)和KDR / Flk-1(VEGFR-2)的单克隆抗体(moAbs)测定28个AML样品中VEGFR-1和VEGFR-2表达的可行性。查阅病历以获取相关的临床信息。在25%(7/28)和43%(12/28)中分别看到VEGFR-1(+)和VEGFR-2(+)的表达。 46%(13/28)是VEG​​FR-1和VEGFR-2的双重阴性; 14%(4/28)是VEG​​FR-1和VEGFR-2的双重阳性。在成纤维细胞表达VEGFR-1(+)或VEGFR-2(+)或两者均表达的患者中,观察到了较差的生存。通过IHS测定PE-BM组织中VEGF受体(1和2)的表达是可行的。必须对IHC与流式细胞仪或其他分子技术进行前瞻性比较,并评估AML患者中VEGF受体的预后意义。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号